RaymondYu JeangWangMD

Medical Genetics • Orange, CA

Clinical Biochemical Genetics, Clinical Genetics

Associate Clinical Professor, Pediatrics, University of California, Irvine College of Medicine

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

Office
1201 W La Veta Blvd
Orange, CA 92868
Phone+1 714-509-8852

Fax+1 714-509-4531

Summary

I am the director of multidisciplinary lysosomal storage disorder program at CHOC Children’s and a board certified clinical geneticist and biochemical genetics specialist.

Batten disease pts highlight CHOC as destination hospital for rare diz families

Rare diseases and rare opportunities

A story of my journey as a physician scientist, blessed to help children and families with rare diseases seeking treatment.

Education & Training

Cedars-Sinai Medical CenterFellowship, Medical Genetics and Genomics, 2006 - 2007
Cedars-Sinai Medical CenterResidency, Pediatrics, 2001 - 2006
David Geffen School of Medicine at UCLAClass of 2001

Certifications & Licensure

CA State Medical License 2002 - 2026
American Board of Medical Genetics and Genomics Clinical Biochemical Genetics
American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Clinical Trials

RGX-111 Gene Therapy in Patients With MPS I Start of enrollment: 2019 Apr 03
Active, not recruiting
Phase 1, Phase 2
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients Start of enrollment: 2019 Nov 01
Active, not recruiting
A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis Start of enrollment: 2021 May 11
Terminated
Phase 1, Phase 2
Early Access Program With Arimoclomol in US Patients With NPC
Available
Cerliponase Alfa Observational Study in the US Start of enrollment: 2020 Aug 19
Active, not recruiting
Cardiovascular Structure and Function in the Mucopolysaccharidoses Start of enrollment: 2021 Oct 13
Recruiting
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) Start of enrollment: 2014 Dec 01
Completed
Phase 3
Registry of Patients Diagnosed With Lysosomal Storage Diseases Start of enrollment: 2022 May 31
Recruiting
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT Start of enrollment: 2023 Feb 03
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Generation of an infantile GM1 gangliosidosis induced pluripotent stem cell line (CHOCi005-A) for disease modeling and therapeutic testing.
Allisandra K Rha, Chloe L Christensen, Shih-Hsin Kan, Jerry F Harb, Perla Andrade-Heckman
Stem Cell Research. 2024-12-01
Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells.
Allisandra K Rha, Shih-Hsin Kan, Perla Andrade-Heckman, Chloe L Christensen, Jerry F Harb
Molecular Genetics and Metabolism. 2024-09-07
Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI-LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thick...
Young Bae Sohn, Raymond Wang, Jane Ashworth, Pierre Broqua, Mireille Tallandier
Molecular Genetics and Metabolism Reports. 2024-03-01

Press Mentions

Gene Therapy in Children with MPS I Showing PromiseMarch 8th, 2023
UCI Earns Designation as CIRM Alpha Clinic with Five-Year, $8 Million GrantOctober 27th, 2022
Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MPS IIIAJuly 7th, 2022
Join now to see all

Grant Support

Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type IEunice Kennedy Shriver National Institute of Child Health and Human Development2023–2028
Alpha Stem Cell ClinicCalifornia Institute of Regenerative Medicine2023–2028
Stable therapy in Pompe disease through genome editingNational Institute of Arthritis and Musculoskeletal and Skin Disease2021–2026

Committees

Member, CalOptima Pharmacy and Therapeutics Committee 2018 - Present
Member, CHOC Clinical Efficacy and Efficiency Committee 2018 - Present

Research History

Principal InvestigatorAs PI of the Campbell Foundation of Caring Laboratory, I supervise efforts to develop CRISPR-based gene editing methods for generation of model systems and therapies for inherited lysosomal storage disorders.2017 - Present

Professional Memberships

Alpha Omega Alpha Honor Medical Society - AOA
Member
Society of Inherited Metabolic Disease
Member
Society for the Study of Inborn Errors of Metabolism
Member
American Society of Cell and Gene Therapy
Member